CRF versione 2.0 del 13-12-2022
NIBIT
Study
Clinical Protocol NIBIT-ML-1
A randomized, run-in, phase II study of nivolumab combined with
ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined with
ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1
Copyright © 2020
FULLCRO S.R.L.
- TUTTI I DIRITTI RISERVATI - P. IVA 12073321007
per contatti riguardanti il progetto
nibit@fullcro.org